BELLICUM PHARMACEUTICALS, INC
BELLICUM PHARMACEUTICALS, INC (BLCM): 2 pipeline candidates · ~12 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
12.3 months
D/E -0.08 · 218% dilution
Lead: Phase 1/Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for BELLICUM PHARMACEUTICALS, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$5.9M
Quarterly Burn
$1.5M
Runway
12.3 mo
Revenue
$1.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in BELLICUM PHARMACEUTICALS, INC's pipeline?
BELLICUM PHARMACEUTICALS, INC (BLCM) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BELLICUM PHARMACEUTICALS, INC's lead drug candidate?
BELLICUM PHARMACEUTICALS, INC's most advanced tracked candidate is bpx-601 (Phase 1/Phase 2) for metastatic castration-resistant prostate cancer and metastatic pancreatic cancer expressing PSCA.
What is BELLICUM PHARMACEUTICALS, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BELLICUM PHARMACEUTICALS, INC has approximately 12.3 months of cash runway.
Who is the CEO of BELLICUM PHARMACEUTICALS, INC?
Richard A. Fair is the chief executive officer of BELLICUM PHARMACEUTICALS, INC (BLCM).
Get the full picture on BELLICUM PHARMACEUTICALS, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.